Chardan Forecasts Over 160% Upside On This Eye Disease-Focused Stock

Chardan  has initiated coverage  on EyePoint Pharmaceuticals Inc  (NASDAQ: EYPT ) with a Buy rating and a price target of $21 based on the company's commercial potential with its lead EYP-1901 for Wet Age-related macular degeneration (AMD). The price target represents an upside of over 160%. The lead program utilizes a bioerodible Durasert formulation. Durasert technology is a micro-implant that can be injected intravitreally in an ... Full story available on Benzinga.com